Vanguard Investments Australia
ACAD icon

Vanguard Investments Australia’s Acadia Pharmaceuticals ACAD Stock Holding History

Vanguard Investments Australia’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$725K Hold
28,667
– – ﹤0.01% 1469
2026
Q1 		$638K Buy
+28,667
New +$685K ﹤0.01% 1469

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Investments Australia's ACAD Position: Q2 2026 in Review

Vanguard Investments Australia held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 28,667 shares worth $725K. The position accounts for ﹤0.01% of the portfolio, ranked #1469.

Vanguard Investments Australia first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Vanguard Investments Australia held 28,667 shares of Acadia Pharmaceuticals worth $725K as of Q2 2026.
  • Vanguard Investments Australia left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1469 holding.
  • Vanguard Investments Australia first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.